PT2076243E - Formulação líquida de g-csf - Google Patents

Formulação líquida de g-csf Download PDF

Info

Publication number
PT2076243E
PT2076243E PT08785714T PT08785714T PT2076243E PT 2076243 E PT2076243 E PT 2076243E PT 08785714 T PT08785714 T PT 08785714T PT 08785714 T PT08785714 T PT 08785714T PT 2076243 E PT2076243 E PT 2076243E
Authority
PT
Portugal
Prior art keywords
csf
liquid formulation
formulation
liquid
Prior art date
Application number
PT08785714T
Other languages
English (en)
Inventor
Heinz Lubenau
Walter Hinderer
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007040932A external-priority patent/DE102007040932A1/de
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of PT2076243E publication Critical patent/PT2076243E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PT08785714T 2007-08-27 2008-08-27 Formulação líquida de g-csf PT2076243E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016763 2007-08-27
DE102007040932A DE102007040932A1 (de) 2007-08-27 2007-08-27 Flüssigformulierung von G-CSF

Publications (1)

Publication Number Publication Date
PT2076243E true PT2076243E (pt) 2014-12-05

Family

ID=39745039

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08785714T PT2076243E (pt) 2007-08-27 2008-08-27 Formulação líquida de g-csf

Country Status (20)

Country Link
US (3) US8562967B2 (pt)
EP (2) EP2471510A1 (pt)
JP (2) JP2010536906A (pt)
KR (1) KR20100044261A (pt)
CN (1) CN101795670A (pt)
AU (1) AU2008291309B2 (pt)
BR (1) BRPI0815280A2 (pt)
CA (1) CA2697376C (pt)
CY (1) CY1115815T1 (pt)
DK (1) DK2076243T3 (pt)
ES (1) ES2524454T3 (pt)
HR (1) HRP20141217T1 (pt)
IL (1) IL204118A (pt)
MX (1) MX2010002348A (pt)
NZ (1) NZ583999A (pt)
PL (1) PL2076243T3 (pt)
PT (1) PT2076243E (pt)
SI (1) SI2076243T1 (pt)
UA (1) UA100245C2 (pt)
WO (1) WO2009027076A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
BR112016021535A8 (pt) * 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
US11896037B2 (en) 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
EP3532029B1 (en) * 2016-10-31 2021-04-28 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
JP3895109B2 (ja) 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
ES2216447T3 (es) 1998-08-17 2004-10-16 Pfizer Products Inc. Composiciones proteicas estabilizadas.
DE60103940T2 (de) 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung

Also Published As

Publication number Publication date
EP2471510A1 (de) 2012-07-04
CA2697376C (en) 2016-07-19
SI2076243T1 (sl) 2015-01-30
US9468685B2 (en) 2016-10-18
WO2009027076A1 (de) 2009-03-05
JP2010536906A (ja) 2010-12-02
EP2076243B1 (de) 2014-10-01
IL204118A (en) 2014-11-30
CY1115815T1 (el) 2017-01-25
CA2697376A1 (en) 2009-03-05
US20150125420A1 (en) 2015-05-07
US8946161B2 (en) 2015-02-03
AU2008291309A1 (en) 2009-03-05
KR20100044261A (ko) 2010-04-29
EP2076243B9 (de) 2015-01-14
ES2524454T3 (es) 2014-12-09
AU2008291309B2 (en) 2013-10-17
EP2076243A1 (de) 2009-07-08
US8562967B2 (en) 2013-10-22
MX2010002348A (es) 2010-07-30
PL2076243T3 (pl) 2015-04-30
US20140030214A1 (en) 2014-01-30
US20100216698A1 (en) 2010-08-26
JP2015038111A (ja) 2015-02-26
HRP20141217T1 (hr) 2015-02-27
CN101795670A (zh) 2010-08-04
BRPI0815280A2 (pt) 2018-11-27
DK2076243T3 (da) 2015-01-05
NZ583999A (en) 2011-10-28
UA100245C2 (uk) 2012-12-10

Similar Documents

Publication Publication Date Title
HK1253355A1 (zh) 含有馬西替坦的治療組合物
HK1211462A1 (en) Liquid formulations of bendamustine
GB2474574B (en) Liquid formulation
PL1975226T3 (pl) Płynna kompozycja do obróbki
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
GB2481881B (en) Liquid formulations
HK1154801A1 (en) Liquid composition comprising cisplatin-coordinating compound
ZA201106703B (en) Use of pharmaceutical compositions containing mesembrenone
HK1154794A1 (en) Liquid oral composition
IL204190A (en) Liquid preparation of g-csf
EP2400840A4 (en) LIQUID STATINE FORMULATIONS
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
GB0822633D0 (en) Formulation
IL213711A0 (en) Pharmaceuticl formulation of nanonised fenofibrate
PT2076243E (pt) Formulação líquida de g-csf
GB0800788D0 (en) Niovel formulation
HK1131039A1 (en) Pharmaceutical use of sophoricoside
GB0814376D0 (en) Formulation
ZA201001654B (en) Liquid formulation of G-CSF
HK1144295A1 (en) Stable liquid formulation
GB0805292D0 (en) Pharmaceutical formulation
GB201013871D0 (en) Liquid formulations
GB201008873D0 (en) Liquid formulations
GB0806445D0 (en) Formulation
GB0817663D0 (en) Formulation